Quantcast

Latest Pneumococcal vaccine Stories

2009-06-11 06:00:00

COLLEGEVILLE, Pa., June 11 /PRNewswire-FirstCall/ -- New data from Phase 3 European clinical trials reinforce that Wyeth's (NYSE: WYE) investigational pneumococcal vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine, 13-valent [Adsorbed]), has the potential to provide coverage against the 13 most prevalent serotypes associated with pneumococcal disease (PD), the leading cause of vaccine-preventable death in children younger than five worldwide. The Phase 3 data presented...

2009-06-04 15:05:00

WASHINGTON, June 4 /PRNewswire-USNewswire/ -- The U.S. Agency for International Development (USAID) yesterday contributed $75 million to improve and expand children's immunization programs in developing countries. The contribution is part of the overall U.S. commitment to global health and the new global health initiative, a 6-year, $63 billion dollar effort announced by President Obama in May. The grant was announced by Deputy Secretary of State Jacob Lew at the Global Alliance for...

2009-05-07 07:00:00

-- Candidate vaccine designed to protect against the 13 most prevalent serotypes associated with pneumococcal disease -- COLLEGEVILLE, Pa., May 7 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the U.S. Food and Drug Administration (FDA) granted priority review to the company's Biologic License Application (BLA) for Prevnar 13*, Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM(197) Protein), which was submitted on March 31....

2009-04-07 12:53:00

- Initiation of a first-in-man Phase I clinical trial in healthy subjects - Study aims to obtain safety and immunogenicity data of this new vaccine candidate - Initial results expected in Q4 2009 - Development of Intercell's Streptococcus pneumoniae vaccine supported by PATH VIENNA, April 7 /PRNewswire/ -- Intercell AG (VSE: ICLL) announced today that a Phase I clinical trial with the company's vaccine candidate IC47 to prevent disease caused by the bacterium Streptococcus pneumoniae has...

ad22b08f9ffe239ffd3d3feccbcccc3a1
2009-03-04 15:05:00

Two new studies released Tuesday show that about one and a half million people across the globe die annually of pneumonia, half of them children under the age of five, the AFP reported. Jean Marie Okwo-Bel of the World Health Organization said pneumonia is a leading killer disease in the world among children under the age of five"”resulting in more deaths than AIDS, measles and malaria combined. India reports some 44 million infections of childhood pneumonia a year, while China has...

2009-01-05 23:36:47

Commonly used pneumococcal polysaccharide vaccines do not appear to be effective in preventing pneumonia, Swiss and British researchers said. Dr. Matthias Egger of the University of Bern, Switzerland, and colleagues said that in many industrialized countries, pneumococcal vaccines are currently recommended to help prevent pneumonia in those age 65 and older, and for younger people with increased risk due to conditions like HIV. The study, a systematic review and meta-analysis, looked at 22...

76ff8d01d54ead57d7c57bf968d2545a1
2008-12-21 12:00:00

Suggests adults with asthma should receive pneumococcal vaccine Mayo Clinic research shows adults with asthma are at increased risk of serious pneumococcal disease caused by Streptococcus pneumoniae, the most common bacteria causing middle ear infections and community acquired pneumonia. It also causes blood stream infections and brain infections. According to the Centers for Disease Control, pneumococcal infection is one of the leading causes of death from a vaccine-preventable disease. The...

2008-12-19 12:23:00

Suggests adults with asthma should receive pneumococcal vaccine ROCHESTER, Minn., Dec. 19 /PRNewswire-USNewswire/ -- Mayo Clinic research shows adults with asthma are at increased risk of serious pneumococcal disease caused by Streptococcus pneumoniae, the most common bacteria causing middle ear infections and community acquired pneumonia. It also causes blood stream infections and brain infections. According to the Centers for Disease Control, pneumococcal infection is one of the leading...

2008-12-03 07:31:00

COLLEGEVILLE, Pa., Dec. 3 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMEA) for approval to market its investigational 13-valent pneumococcal conjugate vaccine (PCV13) for infants and young children. Wyeth is seeking an indication for the prevention of pneumococcal disease (PD) caused by the 13 serotypes included in the investigational...

2008-10-27 12:00:29

WASHINGTON, Oct. 27 /PRNewswire-FirstCall/ -- Data from a pivotal trial and three other Phase 3 studies presented today indicate that Wyeth's investigational 13-valent pneumococcal conjugate vaccine (PCV13) may offer broader protection against pneumococcal disease (PD) in infants and young children compared to Prevnar(R), Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein). Specifically, the data indicate that PCV13 may be as effective as Prevnar (also referred to as PCV7)...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related